Proteomics, the large-scale study of proteins, is critical to many research projects taking place at the medical school. Plans are in place to expand capabilities on the Chicago campus in 2016, which will help scientists use proteins to make breakthroughs in varied fields of study.
A $5 million gift from the Hospira Foundation will establish the Hospira Foundation Professorship in Translational Cancer Biology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Marcus Peter, PhD, professor of Medicine in the Division of Hematology/Oncology, and Ali Shilatifard, PhD, chair of Biochemistry and Molecular Genetics, and Maciej Lesniak, MD, chair of Neurological Surgery, have each been awarded seven-year, $6.4 million grants from the National Cancer Institute.
Northwestern Medicine scientists identified a drug that stops the reproduction of tumor cells in models of primary myelofibrosis and acute myeloid leukemia, a finding that has led to new clinical studies in the Lurie Cancer Center.
Francis Giles, MD, chief of Hematology/Oncology in the Department of Medicine, led a clinical study to test the efficacy and safety of a kinase inhibitor for the treatment of chronic myeloid leukemia.
Northwestern Medicine scientists have shown for the first time that the Myosin 9b gene is correlated with lung cancer tumor formation and metastasis.
A new grant from the National Cancer Institute will help three Chicago universities work together with many of the city’s underserved communities to foster impactful cancer research, education, training and outreach.
A recent study shows that patients treated for colon cancer who regularly drank caffeinated coffee had lower rates of cancer recurrence and mortality.
Northwestern Medicine scientists helped develop an implantable device that detects early breast cancer metastatic cells, a method that may enable physicians to identify cancer spreading in patients while treatments are still viable.
A new study co-authored by a Northwestern Medicine scientist found no significant difference between two popular therapy regimens in patients with a subset of Hodgkin lymphoma.